References
- Ammar HO, Salama HA, Ghorab M, Mahmoud AA. Implication of inclusion complexation of glimepiride in cyclodextrin-polymer systems on its dissolution, stability and therapeutic efficacy. Int J Pharm, 2006;320:53–7
- Attama AA, Nzekwe IT, Nnamani PO, Adikwu MU, Onugu CO. The use of solid self-emulsifying systems in the delivery of diclofenac. Int J Pharm, 2003;262:23–8
- Chopra S, Venkatesan N, Betageri GV. Formulation of lipid bearing pellets as a delivery system for poorly soluble drugs. Int J Pharm, 2013;446:136–44
- Constantinides PP, Scalart JP. Formulation and physical characterization of water-in-oil microemulsions containing long- versus medium-chain glycerides. Int J Pharm, 1997;158:57–68
- Craig D. Polyethyelene glycols and drug release. Drug Dev Ind Pharm, 1990;16:2501–26
- Deboeck A, Maes P, Baudier PR. Pharmaceutical composition containing fenofibrate. US Patent No 5,545,628: Aug 13, 1996
- Franceschinis E, Bortoletto C, Perissutti B, Dal Zotto M, Voinovich D, Realdon N. Self-emulsifying pellets in a lab-scale high shear mixer: Formulation and production design. Powder Tech, 2011;207:113–18
- Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother, 2004;58:173–82
- Heinz A, Gordon KC, McGoverin CM, Rades T, Strachan CJ. Understanding the solid-state forms of fenofibrate–a spectroscopic and computational study. Eur J Pharm Biopharm, 2009;71:100–8
- Jannin V, Musakhanian J, Marchaud D. Approaches for the development of solid and semi-solid lipid-based formulations. Adv Drug Deliv Rev, 2008;60:734–46
- Kanaujia P, Lau G, Widjaja E, Ng WK, Hanefeld A, Fischbach M, Maio M, Tan RBH. Investigating the effect of moisture protection on solid-state stability and dissolution of fenofibrate and ketoconazole solid dispersions. Drug Dev Ind Pharm, 2011;37:1026–35
- Khoo SM, Porter CJH, Charman WN. The formulation of halofantrine as either non-solubilising PEG 6000 or solubilising lipid based solid dispersion: Physical stability and absolute bioavailability assessment. Int J Pharm, 2000;205:65–78
- Li P, Hynes S, Haefele TF, Pudipeddi M, Royce AF, Serajuddin ATM. Development of clinical dosage forms for a poorly water-soluble drug II: Formulation and characterization of a novel solid microemulsion preconcentrate system for oral delivery of a poorly water-soluble drug. J Pharm Sci, 2009;98:1750–64
- Lipinski C. Poor aqueous solubility-an industry wide problem in drug discovery. Am Pharm Rev, 2002;5:82–5
- Mahlin D, Ridell A, Frenning G, Engström S. Solid-state characterization of PEG 4000/monoolein mixtures. Macromolecules, 2004;37:2665–7
- Odeberg JM, Kaufmann P, Kroon KG, Hoglund P. Lipid drug delivery and rational formulation design for lipophilic drugs with low oral bioavailability, applied to cyclosporine. Eur J Pharm Sci, 2003;20:375–82
- Patel AR, Vavia PR. Preparation and in vivo evaluation of SMEDDS (Self-microemulsifying drug delivery system) containing fenofibrate. AAPS J, 2007;9:E344–52
- Seo YG, Kim DH, Ramasamy T, Kim JH, Marasini N, Oh YK, Kim DW, Kim JK, Yong CS, Kim JO, Choi HG. Development of docetaxel-loaded solid self-nanoemulsifying drug delivery system (SNEDDS) for enhanced chemotherapeutic effect. Int J Pharm, 2013;452:412–20
- Serajuddin ATM. Solid dispersion of poorly water soluble drugs: Early promises, subsequent problems and recent breakthroughs. J Pharm Sci, 1999;88:1058–66
- Shah AV, Serajuddin ATM. Development of solid self-emulsifying drug delivery system (SEDDS) I: Use of poloxamer 188 as both solidifying and emulsifying agent for lipids. Pharm Res, 2012;29:2817–32
- Venkatesan N, Yoshimitsu J, Ito Y, Shibata N, Takada K. Liquid filled nanoparticles as a drug delivery tool for protein therapeutics. Biomaterials, 2005;26:7154–63